Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 2;11:63. doi: 10.1038/s41467-019-13710-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Oncomodulin (Ocm) is expressed in type I HCs in striolar/central zones, whereas all HCs are positive for Myosin7a of controls. b, c, j Total HC number is increased in Cyp26b1^−/− (1394 ± 39, P = 0.014, n = 6), but unchanged in Aldh1a3^−/− utricles (1285 ± 28, P = 0.419, n = 5), compared to controls (1229 ± 30, n = 6). b, c, k Percentages of Ocm⁺ HCs (14.3 ± 0.5 in controls, n = 6) are decreased in Cyp26b1^−/− (2.3 ± 0.2, n = 6, p < 0.0001) and increased in Aldh1a3^−/− utricles (28.4 ± 1.4, n = 5, P < 0.0001). b, c, l Percentages of Ocm⁺ HCs in lateral cristae (lc, 36.2 ± 2.7 in controls, n = 5) are reduced in Cyp26b1^−/− (3.2 ± 1.1, n = 3, P = 0.0005), but unchanged in Aldh1a3^−/− mutants (44.1 ± 5.6, n = 4, P = 0.302). d Anti-β-tectorin labels SCs in striolas of utricles. e, f, m β-tectorin⁺ domain, as % of total utricular macular area (17.4 ± 0.9 in controls, n = 5), is reduced in Cyp26b1^−/− (7.4 ± 0.6, n = 4, P = 0.0002) and increased in Aldh1a3^−/− (26.4 ± 1.7, n = 4, P = 0.0003) utricles. g Anti-calbindin labels calyceal nerve endings in striolar/central zones. h, i, n, o Expression and percentage of calbindin-positive area is reduced in utricles (3.8 ± 0.3, n = 3, P = 0.0005) and cristae (4.7 ± 1.4, n = 3, P < 0.0001) of Cyp26b1 cKO, but increased in utricles (36.0 ± 6.6, n = 4, P = 0.0006) and unchanged in cristae (34.4 ± 0.5, n = 3, P = 0.3021) of Aldh1a3^−/− (em RA) mutants, compared to respective controls (n, 19.7 ± 1.7, n = 5; o, 34.2 ± 1.1, n = 3). Error bars: SEM. Significance was assessed by one-way ANOVA for all panels. A, anterior; L, lateral. **P < 0.01 and ***P < 0.001. n.s., not significant. Scale bar: 200 μm.